SCHEMBL15035302

SCHEMBL15035302

CCN(CC)c1cc2cnc(Nc3ccc(C4=CCNCC4)cc3)nc2n(C2Cc3ccccc3S(=O)(=O)C2)c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 18/20 0.42
CDK6 Q00534 4/20 0.42
CCND1 P24385 15/20 0.39
CCNA2 P20248 13/20 0.39
CDK2 P24941 13/20 0.39
FGFR1 P11362 11/20 0.39
FGFR2 P21802 10/20 0.39
FGFR4 P22455 10/20 0.39
FGFR3 P22607 10/20 0.39
CCND2 P30279 1/20 0.36
CCND3 P30281 1/20 0.36
CCNA1 P78396 1/20 0.36
PIK3CD O00329 1/20 0.35
PRKAB2 O43741 1/20 0.35
NUAK1 O60285 1/20 0.35
CCNT1 O60563 1/20 0.35
ABL1 P00519 1/20 0.35
FYN P06241 1/20 0.35
CDK1 P06493 1/20 0.35
CSF1R P07333 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15035419 0.85 CDK4 (0.43) CDK4CDK6CCND1CCNA2CDK2
SCHEMBL15035520 0.82 CDK4 (0.42) CDK4CDK6CCND1CCNA2CDK2
SCHEMBL15041844 0.73 CDK4 (0.47) CDK4CDK6CCND1CCNA2CDK2
SCHEMBL15035485 0.73 CDK4 (0.44) CDK4CDK6CCND1CCNA2CDK2
SCHEMBL15035020 0.72 CDK4 (0.40) CDK4CDK6CCND1CCNA2CDK2
SCHEMBL15035390 0.72 CDK4 (0.39) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL15035250 0.72 TNK2 (0.43) CDK4CDK6FGFR1FGFR2FGFR4
SCHEMBL15035540 0.72 CDK4 (0.44) CDK4CDK6CCND1CCNA2CDK2
SCHEMBL15041620 0.72 CDK4 (0.49) CDK4CDK6CCND1CCNA2CDK2
SCHEMBL15035589 0.72 CDK4 (0.43) CDK4CDK6CCND1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 CDK4 404/4885CDK6 435/4885CCND1 2153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.